calcemin- calcium carbonate tablet, film coated
bayer healthcare llc. - previtamin d3 (unii: hda46400n5) (previtamin d3 - unii:hda46400n5), zinc (unii: j41csq7qds) (zinc - unii:j41csq7qds), boron (unii: n9e3x5056q) (boron - unii:n9e3x5056q) - previtamin d3 0.75 mg
calcemin advance- calcium citrate tablet, film coated
bayer healthcare llc. - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), previtamin d3 (unii: hda46400n5) (previtamin d3 - unii:hda46400n5), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), sodium borate (unii: 91mbz8h3qo) (borate ion - unii:44oae30d22) - calcium carbonate 500 mg
alendronate plus d3 70 mg/140 ug apotex alendronate (as sodium) 70 mg and colecalciferol 140 microgram (5600 iu) tablet blister
dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sucrose; butylated hydroxytoluene; croscarmellose sodium; microcrystalline cellulose; gelatin; medium chain triglycerides; colloidal anhydrous silica - alendronate plus d3 70 mg/140 microgram apotex are indicated for the treatment of: osteoporosis in select patients where vitamin d supplementation is recommended, prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture
alendronate plus d3 70 mg/70 ug apotex alendronate (as sodium) 70 mg and colecalciferol 70 microgram (2800 iu) tablet blister pa
dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: gelatin; povidone; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides; butylated hydroxytoluene; magnesium stearate; sucrose - alendronate plus d3 70 mg/70 microgram apotex are indicated for the treatment of: osteoporosis in select patients where vitamin d supplementation is recommended, prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture
alendronate plus d3 sandoz 70 mg/140 microgram alendronate (as sodium) 70 mg and colecalciferol 140 microgram (5600 iu) tablet b
dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: gelatin; croscarmellose sodium; butylated hydroxytoluene; colloidal anhydrous silica; sucrose; magnesium stearate; microcrystalline cellulose; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture
alendronate plus d3 sandoz 70 mg/70 microgram alendronate (as sodium) and colecalciferol 70 mg/70 microgram (2800 iu) tablet bli
dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; gelatin; croscarmellose sodium; medium chain triglycerides; microcrystalline cellulose; magnesium stearate; sucrose; butylated hydroxytoluene - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture
apo-alendronate/vitamin d3 tablet
apotex inc - alendronic acid (alendronate sodium); vitamin d3 (cholecalciferol) - tablet - 70mg; 2800unit - alendronic acid (alendronate sodium) 70mg; vitamin d3 (cholecalciferol) 2800unit - vitamin d
apo-alendronate/vitamin d3 tablet
apotex inc - alendronic acid (alendronate sodium); vitamin d3 (cholecalciferol) - tablet - 70mg; 5600unit - alendronic acid (alendronate sodium) 70mg; vitamin d3 (cholecalciferol) 5600unit - vitamin d
alendronate plus d3
dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sucrose; butylated hydroxytoluene; croscarmellose sodium; microcrystalline cellulose; gelatin; medium chain triglycerides; colloidal anhydrous silica - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture
alendronate plus d3
dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: gelatin; povidone; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides; butylated hydroxytoluene; magnesium stearate; sucrose - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture